Ϫ absorption induced by 1,25(OH)2D3 were significantly greater than those in the absence of aldosterone (P Ͻ 0.05). The effect of aldosterone to potentiate inhibition by 1,25(OH) 2D3 was not affected by spironolactone but was eliminated by the MAPK kinase/ERK inhibitor U-0126. U-0126 did not affect inhibition of HCO 3 Ϫ absorption by 1,25(OH) 2D3 alone. Aldosterone induced rapid activation of ERK via a transcription-independent pathway. We conclude that 1) 1,25(OH) 2D3 inhibits HCO 3 Ϫ absorption in the MTAL via a genomic pathway involving protein kinase C, which may contribute to 1,25(OH) 2D3-induced regulation of urinary net acid and/or Ca 2ϩ excretion and 2) aldosterone potentiates inhibition by 1,25(OH) 2D3 through an ERK-dependent, nongenomic pathway. These results identify a novel regulatory interaction whereby aldosterone acts via nongenomic mechanisms to enhance the genomic response to 1,25(OH) 2D3. Aldosterone may influence a broad range of biological processes, including epithelial transport, by modifying the response of target tissues to 1,25(OH) 2D3 stimulation.
sis, steroid hormones have been recognized recently to induce rapid cellular responses that occur independently of transcription and translation (12) . Nongenomic effects have been identified for all groups of steroids, including aldosterone, glucocorticoids, progesterone and estrogen, and vitamin D 3 (7-10, 12, 22, 33) . The biological and clinical relevance of rapid steroid effects is not well understood. Nongenomic pathways have been implicated in a variety of important processes, including endothelial cell biology, cardiovascular function and blood pressure, fertility, neuronal excitability, and electrolyte homeostasis (7-10, 12, 22, 23, 33, 34) . The rapid steroid effects likely are transmitted through cell-surface receptors (10, 12, 23, 36, 46) , and there is increasing evidence that steroid hormones may control their own transcriptional regulation through the rapid activation of second messenger pathways (7) (8) (9) (10) 12) . However, the physiological significance of interactions between nongenomic and genomic mechanisms in steroid-induced regulation is poorly defined.
Aldosterone plays a major role in Na ϩ , K ϩ , and H ϩ homeostasis through transcriptional regulation of electrolyte transport across renal tubule epithelia (1, 37, 43) . Recently, we demonstrated that aldosterone inhibits transepithelial HCO 3 Ϫ absorption in the medullary thick ascending limb (MTAL) of the rat via a pathway that is highly selective, operates independently of transcription and translation, and is not mediated through the classical mineralocorticoid receptor (20) . This nongenomic regulation is observed with physiological aldosterone concentrations and is blocked by inhibitors of the extracellular signal-regulated kinase (ERK) signaling pathway (19, 20) . These studies provided the first evidence that nongenomic mechanisms mediate steroid-induced regulation of the transport function of renal tubules. Whether steroid hormones in addition to aldosterone influence renal tubule function through nongenomic actions has not been determined. How nongenomic and genomic steroid pathways may interact to regulate renal tubule transport also is unknown.
1␣,25-Dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ], the major active metabolite of vitamin D 3 , plays a crucial role in the regulation of Ca 2ϩ and phosphate balance through its integrated actions on the intestine, kidney, bone, and parathyroid glands (7, 28, 42) . Most of the biological actions of 1,25(OH) 2 D 3 are mediated through transcriptional regulation of target genes after the hormone binds to the nuclear vitamin D receptor (VDR) (7, 28) . However, 1,25(OH) 2 D 3 also activates nongenomic signaling pathways in some systems (7, 12) . 1,25(OH) 2 D 3 influences a variety of renal functions, including reabsorption of Ca 2ϩ and phosphate and excretion of acid (7, 14, 25, 41, 42) . It is unclear to what extent these effects are mediated through direct actions of 1,25(OH) 2 D 3 on the renal tubules or through indirect effects of the hormone on plasma Ca 2ϩ concentration, parathyroid hormone (PTH) levels, or other confounding factors (7, 25, 42) . The VDR is expressed in multiple nephron segments (26, 30) The purpose of the present study was to examine directly the effects of 1,25(OH) 2 D 3 on HCO 3 Ϫ absorption by the MTAL of the rat and to determine whether nongenomic mechanisms are involved in mediating 1,25(OH) 2 D 3 -induced transport regulation. Interactions between 1,25(OH) 2 D 3 -and aldosterone-induced regulatory pathways also were investigated.
METHODS
All experimental procedures were approved by the University of Texas Medical Branch Animal Care and Use Committee.
Tubule Perfusion and Measurement of Net HCO 3
Ϫ Absorption MTAL from male Sprague-Dawley rats (50-100 g body wt; Taconic, Germantown, NY) were isolated and perfused in vitro as described previously (18, 20, 49, 50) . The rats had free access to standard chow (NIH 31 diet; Ziegler) and distilled H 2O. Tubules were dissected from the inner stripe of the outer medulla at 10°C in control bath solution (see below), transferred to a bath chamber on the stage of an inverted microscope, and mounted on concentric glass pipettes for perfusion at 37°C. In all experiments, the lumen and bath solutions contained (in mM) 146 Na Bath solutions also contained 0.2% fatty acid-free bovine albumin. All solutions were equilibrated with 95% O 2-5% CO 2; pH was 7.45 at 37°C. Bath solutions were delivered to the perfusion chamber via a continuously flowing exchange system. To maintain constant pH and O 2 tension surrounding the tubules, the bath solutions were delivered through lines jacketed with 95% O 2-5% CO2, and the perfusion chamber was suffused continuously with the same gas mixture (21) . Experimental agents were added to the bath solutions as described in RESULTS. 1,25(OH)2D3 (Sigma) was prepared as a stock solution in ethanol and diluted into bath solutions to final concentrations given in RESULTS. Solutions containing aldosterone and other experimental agents were prepared as described (18, 20, 50) . Equal concentrations of vehicle were added to control solutions in all protocols.
The protocol for study of transepithelial HCO 3 Ϫ absorption has been described elsewhere (18, 20, 49) . In most experiments, tubules were equilibrated for 20-30 min at 37°C in the initial perfusion and bath solutions, and the luminal flow rate (normalized per unit tubule length) was adjusted to 1.6-2.0 nl ⅐ min Ϫ1 ⅐ mm Ϫ1 . One to five 10-min tubule fluid samples were then collected for each period (initial, experimental, and recovery). The tubules were allowed to reequilibrate for 5-10 min after an experimental agent was added to or removed from the bath solution. In some experiments, longer treatment periods were used. The absolute rate of HCO 3 Ϫ absorption was calculated from the luminal flow rate, and the difference between total CO 2 concentrations measured in perfused and collected fluids (18, 20) . An average HCO 3 Ϫ absorption rate was calculated for each period studied in a given tubule. When repeat measurements were made at the beginning and end of an experiment (initial and recovery periods), the values were averaged. Single tubule values are presented in Figs. 1-5. Values are means Ϯ SE; n is the number of tubules. The absolute decrease in HCO 3 Ϫ absorption was calculated for individual tubules as the difference between absorption rates measured in the absence and pres- Fig. 1 
Determination of ERK Activity
The inner stripe tissue preparation used to study ERK activity in the MTAL has been described (48, 50) . Briefly, thin strips of tissue were dissected at 4°C from the inner stripe of the outer medulla, the region of the kidney highly enriched in MTAL (3, 48) . The strips were divided into four samples of equal amount and incubated in vitro at 37°C in the same solutions used for HCO 3 Ϫ transport experiments. In one series of experiments, tissue samples were equilibrated in control solution for 90 min in the absence and presence of actinomycin D (12.5 g/ml) and then maintained in control solution or treated with 1 nM aldosterone for 15 min. In a second series, tissue samples were equilibrated for 30 min in the absence and presence of 15 M U-0126 before aldosterone treatment. After incubation, the tissue was lysed and ERK1/2 activity was measured in an immune complex kinase assay, with myelin basic protein used as substrate, as described previously (48, 50) . Phosphorylated substrate was isolated by SDS-PAGE, visualized by autoradiography, and quantified by densitometry (48, 50) . Equal amounts of ERK in different experimental conditions were verified in parallel samples by immunoblotting. We demonstrated previously that changes in protein kinase activities measured in the inner stripe accurately reproduce changes in the MTAL (3, 48, 50) . 2 Effects of protein kinase C inhibitors. Activation of protein kinase C (PKC) mediates certain cellular effects of 1,25(OH) 2 D 3. The role of PKC in the inhibition of HCO 3 Ϫ absorption was examined using chelerythrine chloride and staurosporine, PKC inhibitors that selectively block PKC-dependent regulation of HCO 3 Ϫ absorption in the MTAL (3, (17) (18) (19) . In tubules bathed with 10 Ϫ7 M chelerythrine chloride or 10 Ϫ7 M staurosporine, addition of 1 nM 1,25(OH) 2 D 3 to the bath had Ϫ, data points, lines, and P values are as described in Fig. 1A legend. NS, not significant. no effect on HCO 3 Ϫ absorption: 11.6 Ϯ 0.3, inhibitors vs. 11. (Fig. 3) . These results suggest that 1,25(OH) 2 D 3 inhibits HCO 3 Ϫ absorption via a PKCdependent pathway.
RESULTS

Effects of 1,25(OH)
7 Ϯ 0.3 pmol ⅐ min Ϫ1 ⅐ mm Ϫ1 , inhibitors ϩ 1,25(OH) 2 D 3
Interaction of 1,25(OH) 2 D 3 and Aldosterone
1,25(OH) 2 D 3 inhibits HCO 3
Ϫ absorption in the MTAL through gene regulation, whereas inhibition by aldosterone is transcription and translation independent (20) . Further experiments were carried out to investigate how these different pathways interact to regulate MTAL function.
Aldosterone potentiates inhibition by 1, 25(OH) 2 D 3 . In MTAL bathed with 1 nM aldosterone for 15-20 min, 1 nM 1,25(OH) 2 D 3 decreased HCO 3 Ϫ absorption by 48% (from 11.7 Ϯ 0.5 to 6.1 Ϯ 0.4 pmol ⅐ min Ϫ1 ⅐ mm
Ϫ1
, P Ͻ 0.001) compared with a decrease of 24% observed under the same conditions in the absence of aldosterone (Fig. 4, A and B) . The absolute and fractional decreases in HCO 3 Ϫ absorption induced by 1,25(OH) 2 D 3 were significantly greater in the presence than in the absence of aldosterone (Fig. 4, E and F , aldosterone ϩ actinomycin D ϩ 1,25(OH) 2 D 3 (n ϭ 4, P ϭ not significant).
Further studies were designed to determine whether aldosterone influences 1,25(OH) 2 D 3 -induced regulation through nongenomic mechanisms. We previously identified two key features of the nongenomic pathway activated by aldosterone in the MTAL: 1) it is blocked by inhibitors of ERK activation, and 2) it is not affected by spironolactone, a competitive antagonist of the classical mineralocorticoid receptor (19, 20) . We took advantage of these properties to test whether this non- U-0126 blocks potentiation by aldosterone. U-0126 is a selective inhibitor of the MAPK kinase MEK1/2, which directly activates ERK1/2 (13, 50). U-0126 blocks ERK activation in the MTAL and prevents the nongenomic inhibition of HCO 3 Ϫ absorption by aldosterone (19, 48, 50) . We therefore tested whether U-0126 would influence the effect of aldosterone to potentiate inhibition by 1,25(OH) 2 D 3 . In MTAL bathed with 1 nM aldosterone ϩ 15 M U-0126, 1 nM 1,25(OH) 2 D 3 decreased HCO 3 Ϫ absorption by 21% (from 14.5 Ϯ 1.1 to 11.4 Ϯ 1.1 pmol ⅐ min Ϫ1 ⅐ mm Ϫ1 , P Ͻ 0.001; Fig. 4D ), an amount similar to that observed with 1,25(OH) 2 D 3 alone (Fig. 4A) . The effect of aldosterone to enhance the absolute and fractional inhibition of HCO 3 Ϫ absorption by 1,25(OH) 2 D 3 was eliminated completely by U-0126 (Fig. 4, E and F) . In contrast, U-0126 had no effect on the inhibition of HCO 3 Ϫ absorption by 1,25(OH) 2 D 3 in the absence of aldosterone (Fig. 4, C, E, and F) , indicating that ERK is not involved in mediating inhibition by 1,25(OH) 2 D 3 and that the MEK/ERK inhibitor blocked specifically the regulatory action of aldosterone. These results indicate that aldosterone potentiates the inhibition by 1,25(OH) 2 D 3 via an ERK-dependent mechanism and support the view that aldosterone acts via its nongenomic pathway.
Spironolactone does not block potentiation by aldosterone. In MTAL bathed with 1 nM aldosterone ϩ 10 M spironolactone, 1 nM 1,25(OH) 2 D 3 decreased HCO 3 Ϫ absorption from 11.7 Ϯ 0.5 to 5.5 Ϯ 0.4 pmol ⅐ min Ϫ1 ⅐ mm Ϫ1 (P Ͻ 0.001; Fig. 5 ). The absolute (6.2 Ϯ 0.2 pmol ⅐ min Ϫ1 ⅐ mm
) and fractional (53 Ϯ 2%) decreases in HCO 3 Ϫ absorption were similar to those induced by 1,25(OH) 2 D 3 in the presence of aldosterone alone and were greater than the decreases observed with 1,25(OH) 2 D 3 in the absence of aldosterone (Fig. 4,  E and F) . Thus the potentiation of 1,25(OH) 2 D 3 action by aldosterone is not blocked by spironolactone and, therefore, not mediated through the classical mineralocorticoid receptor.
Aldosterone activates ERK via a transcription-independent mechanism. Results of the preceding experiments support the view that aldosterone acts through a nongenomic pathway involving ERK to potentiate inhibition by 1,25(OH) 2 D 3 . To confirm directly that aldosterone activates ERK via a nongenomic mechanism, inner stripe tissue was incubated in vitro in the absence and presence of aldosterone for 15 min, and then ERK activity was assessed by immune complex assay (48, 50) . Incubation with 1 nM aldosterone increased ERK activity 1.6 Ϯ 0.1-fold (n ϭ 3, P Ͻ 0.05), and this increase was not prevented by pretreatment with actinomycin D (Fig. 6, A and B) . These results demonstrate that aldosterone increases ERK activity via a transcription-independent pathway. The aldosterone-induced ERK activation was blocked completely by pretreatment with 15 M U-0126 (Fig. 6C) . Immunoblot analysis of inner stripe samples using antiphospho-ERK1/2 antibody showed that aldosterone increased ERK phosphorylation (results not shown).
DISCUSSION
The major findings of this study are that 1) 1,25(OH) 2 D 3 inhibits HCO 3 Ϫ absorption in the MTAL via a genomic pathway likely involving PKC, and 2) aldosterone potentiates the inhibition by 1,25(OH) 2 D 3 through a nongenomic pathway involving ERK activation. These results, to our knowledge, are the first in any system to identify a direct interaction between aldosterone and 1,25(OH) 2 D 3 in the regulation of cell function and demonstrate that this interaction is the result of cross talk between nongenomic and genomic steroid hormone signaling pathways. Although nongenomic actions of aldosterone have been demonstrated in a variety of cell systems (12, 33) , their physiological relevance to the regulation of epithelial transport has been unclear. Our results in the MTAL establish that nongenomic pathways activated by aldosterone not only regulate transepithelial transport directly (20) but also can modify the transport response to other, dissimilar steroid hormones. 2 2Ϫ , and net acid, but very little is known about the direct effects of this hormone on the transport function of individual nephron segments (7, 14, 25, 28, 41, 42 (26, 30) , a member of the nuclear receptor superfamily that mediates 1,25(OH) 2 D 3 -induced transcriptional regulation (7, 28) . Whether the VDR is involved in inhibition of HCO 3 Ϫ absorption in the MTAL remains to be determined.
1,25(OH)
The Na ϩ /H ϩ exchanger isoform NHE3 is localized selectively in the apical membrane of certain renal and intestinal epithelial cells, where it mediates transepithelial reabsorption of NaCl and/or NaHCO 3 (35, 44) . It is unknown whether the activity of this transporter is regulated by 1,25(OH) 2 D 3 . NHE3 mediates virtually all the luminal H ϩ secretion necessary for HCO 3 Ϫ absorption in the MTAL (2, 4, 21, 49) . Thus it is highly likely that 1,25(OH) 2 D 3 inhibits NHE3 in the MTAL. Further direct studies of the effect of 1,25(OH) 2 D 3 on the apical Na ϩ /H ϩ exchanger are needed to determine whether the 1,25(OH) 2 D 3 -induced signaling pathway is coupled directly to inhibition of the exchanger or whether 1,25(OH) 2 D 3 may act indirectly to decrease exchanger activity through effects on another transporter, such as basolateral HCO 3 Ϫ efflux pathways or the Na ϩ -K ϩ -ATPase. It is noteworthy that inhibition of HCO 3 Ϫ absorption by 1,25(OH) 2 D 3 likely involves PKC, which has been reported to inhibit NHE3 in some systems (35, 44) . However, in the MTAL, neither activation nor inhibition of PKC by itself leads to inhibition of HCO 3 Ϫ absorption (3, 18). Thus it is unlikely that PKC is a direct mediator of 1,25(OH) 2 D 3 -induced inhibition of apical Na reduces the abundance of the apical Na ϩ -K ϩ -2Cl Ϫ cotransporter (BSC-1 or NKCC2) and the apical K ϩ channel (ROMK), effects that would reduce MTAL NaCl absorption and contribute to the urinary concentrating defect associated with hypercalcemia (45) . The adaptations in the two MTAL transporters were explained on the basis of renal and cellular responses to hypercalcemia (45) . However, our results raise the additional possibility that the adaptations in BSC-1 and ROMK observed in these studies may involve direct receptormediated effects of 1,25(OH) 2 D 3 on the MTAL.
Aldosterone Potentiates Inhibition by 1, 25(OH) 2 D 3 In the presence of aldosterone, the inhibition of Ϫ absorption by aldosterone (19, 20) , 3) inhibitors of ERK activation eliminate the potentiating effect of aldosterone on 1,25(OH) 2 D 3 but have no effect on the inhibition of HCO 3 Ϫ absorption by 1,25(OH) 2 D 3 alone, 4) 1,25(OH) 2 D 3 action is potentiated by short-term (15 min) aldosterone treatment, and 5) potentiation by aldosterone is not prevented by spironolactone, indicating that it does not involve the classical mineralocorticoid receptor. Much recent attention has been focused on the possibility that steroid hormones may act through genomic and nongenomic mechanisms simultaneously, whereby rapid activation of nongenomic signals by a steroid may, in turn, modulate its genomic response (8) (9) (10) 12) . Our results broaden this concept by demonstrating that the activation of nongenomic pathways by one steroid can modify the genomic response to another, dissimilar steroid. These findings identify novel mechanisms through which aldosterone may influence electrolyte transport in the kidney and through which tissue-specific regulation by aldosterone could be achieved. In addition, they present new therapeutic options whereby the biological response to a particular steroid such as 1,25(OH) 2 D 3 could be modified through pharmacological manipulation of nongenomic mechanisms activated by a different steroid hormone in the same cell.
The mechanism(s) by which aldosterone potentiates regulation by 1,25(OH) 2 D 3 remain to be defined, but some possibilities can be considered on the basis of findings in other systems. The interaction could involve cross talk between the aldosterone-induced ERK pathway and PKC, which appears to be an essential component of the 1,25(OH) 2 D 3 regulatory pathway. Alternatively, the ERK-dependent pathway activated by aldosterone could alter the transcriptional activity of the VDR through receptor phosphorylation or by alteration of the activity of coactivator proteins (28) . One such coactivator may be the retinoid X receptor, which heterodimerizes with the VDR and is essential for its DNA-binding and transcriptional activity (7, 28) . Recent work suggests that the retinoid X receptor can be specifically phosphorylated and regulated through the Ras-MEK-ERK cascade (11, 27) . These and other possible mechanisms need to be tested experimentally in the future. Our results suggest, however, that ERK is an important mediator of cross talk between nongenomic and genomic steroid regulatory pathways.
Physiological Significance and Clinical Implications
The direct action of 1,25(OH) 2 (42) . Our findings suggest the novel possibility that direct aldosterone-1,25(OH) 2 D 3 interactions could contribute to this relation. For example, 1,25(OH) 2 D 3 -dependent stimulation of Ca 2ϩ absorption in distal nephron segments could be potentiated by increased aldosterone levels during volume depletion. Conceivably that interaction could promote hypercalcemia that may contribute to vasoconstriction in volume-contracted states. Direct tests of these hypotheses will require future studies of the interacting effects of aldosterone and 1,25(OH) 2 D 3 on Ca 2ϩ absorption in multiple nephron segments and direct analysis of the role of luminal HCO 3 Ϫ as a determinant of distal nephron Ca 2ϩ absorption. The discovery of a functional interaction between 1,25(OH) 2 D 3 and aldosterone has additional, broader implications. In addition to its role in Ca 2ϩ and phosphate homeostasis, 1,25(OH) 2 D 3 influences a wide variety of other biological processes, including the immune response, insulin secretion, cardiovascular function, and blood pressure (7, 24, 28, 40, 47) . Several 1,25(OH) 2 D 3 target tissues, including intestinal epithelial cells and the cardiovascular system, also have been identified as sites of nongenomic aldosterone regulation (12, 22, 33) . Our results raise the possibility that aldosterone could influence a broad range of physiological and pathophysiological processes, such as intestinal Ca 2ϩ absorption, vascular inflammation and calcification, and blood pressure, by modifying the response of target tissues to 1,25(OH) 2 D 3 stimulation. This possibility is supported by recent work indicating that aldosterone may influence blood pressure by acting through nongenomic mechanisms to modulate vascular responses to adrenergic stimulation (33, 38) . Finally, 1,25(OH) 2 D 3 has been identified recently as a regulator of the renin-angiotensin-aldosterone system (32) . In normal mice, inhibition of 1,25(OH) 2 D 3 synthesis increased, whereas 1,25(OH) 2 D 3 administration decreased, renin production. Furthermore, in VDR-null mice, renin production was elevated, leading to increased angiotensin II levels and hypertension (32) . Our results suggest that increased aldosterone levels induced by 1,25(OH) 2 D 3 deficiency could enhance 1,25(OH) 2 D 3 actions in the kidney and other target tissues, thereby maintaining 1,25(OH) 2 D 3 -dependent regulation despite reduced circulating hormone levels. In this way, aldosterone could serve as the effector in a feedback system whereby the renin-angiotensin-aldosterone system helps mitigate against the highly detrimental systemic consequences of 1,25(OH) 2 D 3 deficiency.
